Skip to main content

This artificial heart could help keep people on transplant waiting lists alive

Promotional image for Tech For Change. Person standing on solar panel looking at sunset.
This story is part of Tech for Change: an ongoing series in which we shine a spotlight on positive uses of technology, and showcase how they're helping to make the world a better place.
Carmat TAH 3D video - Presentation

A French company called Carmat has created an artificial heart that could potentially help save the lives of people with end-stage biventricular heart failure. And, no, this isn’t some piece of future tech that won’t be available for another decade or so; it has already been used on actual patients — including one who  had the implanted heart two years ago. And it’s coming to the United States.

Recommended Videos

“The idea behind this heart, which was born nearly 30 years ago, was to create a device which would replace heart transplants, a device that works physiologically like a human heart, one that’s pulsating, self-regulated, and compatible with blood,” Carmat CEO Stéphane Piat recently told Reuters.

The artificial heart, which weighs about three times what the average human heart weighs, boasts two ventricles — one for blood, the other for hydraulic fluid — separated by a membrane. Hydraulic fluid is moved in and out using a motorized pump, which moves the membrane so that the blood can flow. In-built electronics, sensors, and microprocessors can autonomously regulate the blood flow in response to the activity of the patient, who must carry a bag of actuator fluid, a lithium-ion battery, and a controller.

Heart
Carmat

“Carmat aims to meet a major public health challenge related to cardiovascular diseases, namely heart failure, the leading cause of death in the world,” the company notes on its website. “More specifically, Carmat aims to provide a lasting solution to the treatment of terminal heart failure, a disease for which there are very few effective options today, the main one being heart transplants.”

The artificial heart has reportedly received the necessary CE marking in Europe to show that it is in line with health and safety standards. It received this approval last year, and will launch in both Germany and France in the second quarter of 2021. According to SingularityHub, Carmat has also received U.S. Food and Drug Administration permission for an early feasibility study in the United States. That will take place this year as well.

With thousands of biventricular heart failure patients currently on transplant waiting lists around the world, this could be a massive game changer that helps solve a major real-world problem.

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Google just gave vision to AI, but it’s still not available for everyone
Gemini Live App on the Galaxy S25 Ultra broadcast to a TV showing the Gemini app with the camera feature open

Google has just officially announced the roll out of a powerful Gemini AI feature that means the intelligence can now see.

This started in March as Google began to show off Gemini Live, but it's now become more widely available.

Read more
This modular Pebble and Apple Watch underdog just smashed funding goals
UNA Watch

Both the Pebble Watch and Apple Watch are due some fierce competition as a new modular brand, UNA, is gaining some serous backing and excitement.

The UNA Watch is the creation of a Scottish company that wants to give everyone modular control of smartwatch upgrades and repairs.

Read more
Tesla, Warner Bros. dodge some claims in ‘Blade Runner 2049’ lawsuit, copyright battle continues
Tesla Cybercab at night

Tesla and Warner Bros. scored a partial legal victory as a federal judge dismissed several claims in a lawsuit filed by Alcon Entertainment, a production company behind the 2017 sci-fi movie Blade Runner 2049, Reuters reports.
The lawsuit accused the two companies of using imagery from the film to promote Tesla’s autonomous Cybercab vehicle at an event hosted by Tesla CEO Elon Musk at Warner Bros. Discovery (WBD) Studios in Hollywood in October of last year.
U.S. District Judge George Wu indicated he was inclined to dismiss Alcon’s allegations that Tesla and Warner Bros. violated trademark law, according to Reuters. Specifically, the judge said Musk only referenced the original Blade Runner movie at the event, and noted that Tesla and Alcon are not competitors.
"Tesla and Musk are looking to sell cars," Reuters quoted Wu as saying. "Plaintiff is plainly not in that line of business."
Wu also dismissed most of Alcon's claims against Warner Bros., the distributor of the Blade Runner franchise.
However, the judge allowed Alcon to continue its copyright infringement claims against Tesla for its alleged use of AI-generated images mimicking scenes from Blade Runner 2049 without permission.
Alcan says that just hours before the Cybercab event, it had turned down a request from Tesla and WBD to use “an icononic still image” from the movie.
In the lawsuit, Alcon explained its decision by saying that “any prudent brand considering any Tesla partnership has to take Musk’s massively amplified, highly politicized, capricious and arbitrary behavior, which sometimes veers into hate speech, into account.”
Alcon further said it did not want Blade Runner 2049 “to be affiliated with Musk, Tesla, or any Musk company, for all of these reasons.”
But according to Alcon, Tesla went ahead with feeding images from Blade Runner 2049 into an AI image generator to yield a still image that appeared on screen for 10 seconds during the Cybercab event. With the image featured in the background, Musk directly referenced Blade Runner.
Alcon also said that Musk’s reference to Blade Runner 2049 was not a coincidence as the movie features a “strikingly designed, artificially intelligent, fully autonomous car.”

Read more